Transient OSK pulses combined with senolytic clearance of p53-high cells prevent epigenetic age rebound and yield durable rejuvenation
Hypothesis
Combining short inducible OSK expression (2 days on/5 days off) with a senolytic regimen administered immediately after each OSK pulse will block the p53‑dependent epigenetic rebound that limits current partial reprogramming approaches, resulting in sustained reversal of epigenetic age markers without increasing tumorigenicity.
Mechanistic Rationale
Partial reprogramming with OSK resets DNA methylation and restores mitochondrial function, but epigenetic age reverts when treatment stops, likely due to reactivation of the p53 pathway that re‑establishes repressive chromatin states at pluripotency loci [[2]]. Senescent cells accumulate with age and secrete a SASP that reinforces p53 activation and promotes DNA methyltransferase activity, creating a feedback loop that drives re‑methylation after OSK withdrawal [[5]]. Removing p53-high/senescent cells with a senolytic (e.g., dasatinib+quercetin) immediately after each OSK pulse should interrupt this loop, allowing the epigenetically reset state to be maintained through improved DNA repair and reduced inflammatory signaling.
This rationale extends the observation that rejuvenation can occur without dedifferentiation when exposure is brief [[4]]; by coupling the brief OSK window with senolysis, we aim to "lock in" the youthful epigenome before p53‑mediated rebound can act.
Experimental Design
Animal model: 124‑week‑old C57BL/6 mice (n=15 per group). Groups:
- Control (vehicle).
- OSK pulse only (2 days doxycycline on/5 days off, cyclic for 6 months).
- Senolytic only (dasatinib 5 mg/kg + quercetin 50 mg/kg, IP, once weekly).
- OSK + senolytic (senolytic administered 24 h after each OSK doxycycline off‑day). Readouts (baseline, monthly, and at endpoint):
- Epigenetic clock (Horvath mouse) in blood, liver, brain.
- Tissue‑specific methylation arrays to assess durability.
- p53 target gene expression (p21, Mdm2) by qPCR.
- Senescence markers (SA‑β‑gal, p16Ink4a) via immunostaining.
- Tumor incidence and histopathology.
- Functional assays: grip strength, treadmill endurance, retinal function.
- Lifespan (median and 90th percentile).
Predicted Outcomes
If the hypothesis is correct, group 4 will show:
- A significant and sustained reduction in epigenetic age (≥30% reversal) that persists after the final OSK cycle, unlike group 2 where age rebounds within 4 weeks of cessation.
- Lower p53 target expression and reduced senescence marker load compared with group 2.
- No increase in tumor incidence relative to controls, mirroring the safety of OSK‑only regimens [[2]].
- Improved functional endpoints and extended median lifespan beyond the 109% increase seen with OSK alone [[1]].
Groups 2 and 3 are expected to recapitulate prior findings: transient rejuvenation with rebound (OSK only) and modest senolytic benefits without epigenetic reset.
Potential Confounds and Mitigations
Senolytic toxicity: Dasatinib/quercetin can cause platelet toxicity; we will monitor blood counts and adjust dose if needed. Off‑target effects of doxycycline: Include a doxycycline‑control group receiving doxycycline without OSK transgene. Variability in senolytic timing: Pilot experiments will determine the optimal window (6‑24 h post‑OSK) for senescent cell clearance based on p21 induction kinetics.
Conclusion
By directly targeting the p53‑senescence feedback loop that drives epigenetic rebound, this combined strategy tests whether durable epigenetic rejuvenation is achievable without elevating cancer risk. A positive outcome would provide a mechanistic bridge between transient reprogramming and long‑term age reversal, informing future clinical protocols that pair inducible OSK vectors with intermittent senolytic adjuncts.